Effect of Project Orbis participation by the Swiss regulator on submission gaps, review times, and drug approval decisions between 2020 and 2022: a comparative analysis
Matea Zosso-Pavic, Qiyu Li, Eiman Atiek, Anita Wolfer, Ulrich‐Peter Rohr
Topics & Concepts
Drug approvalPolitical scienceRegulatorDrugLaw and economicsLawPharmacologyMedicineEconomicsChemistryBiochemistryGeneBiomedical Ethics and RegulationHealth Systems, Economic Evaluations, Quality of LifePharmaceutical Economics and Policy